科倫藥業(002422.SZ):4個產品擬中標全國藥品集中採購
格隆匯 8 月 21日丨科倫藥業(002422.SZ)公佈,2020年8月20日,公司及全資子公司湖南科倫製藥有限公司(“湖南科倫”)參加了聯合採購辦公室(“聯採辦”)組織的第三批全國藥品集中採購的投標工作。公司的枸櫞酸託法替布片(5mg)、氫溴酸西酞普蘭片(20mg)/氫溴酸西酞普蘭膠囊(20mg)、鹽酸達泊西汀片(30mg/60mg)、阿莫西林顆粒(0.125g)擬中標此次集中採購,且公司根據各省市場潛力進行了省份遴選。
此次集中採購是國家組織的第三批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施,將進一步擴大相關產品的銷售,提高市場佔有率,提升公司品牌影響力,對公司的未來經營業績具有積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.